Today: 21 May 2026
Dow slides again as bank earnings and China tech curbs hit Wall Street
14 January 2026
2 mins read

Dow slides again as bank earnings and China tech curbs hit Wall Street

NEW YORK, Jan 14, 2026, 13:41 EST — Market open for regular trading.

  • Dow drops for a second day, dragged down by falling bank stocks and widening tech sector declines.
  • New U.S. data fueled hopes for rate cuts, yet investors remained cautious about policy risks.
  • Attention shifts to the Fed’s Beige Book out later Wednesday and the upcoming earnings reports.

The Dow Jones Industrial Average dipped again Wednesday, pressured by a retreat in bank stocks and fresh selling in tech shares. By afternoon, the Dow had dropped 0.60% to 48,894.60. The S&P 500 declined 1.09%, and the Nasdaq Composite fell 1.60%.

The pullback follows closely on the heels of record closing highs for the Dow and S&P 500. Investors now face the tricky task of balancing the kickoff of earnings season with an uptick in policy chatter. Meanwhile, a Justice Department probe into Federal Reserve Chair Jerome Powell has fueled ongoing concerns about the Fed’s independence.

Tuesday’s mood turned grim early. The Dow tumbled 398.21 points, down 0.80%, after JPMorgan leaders flagged concerns that President Donald Trump’s plan to cap credit-card interest rates at 10% might hurt both consumers and the bank’s profits.

Wednesday saw selling accelerate after major banks reported mixed earnings. Wells Fargo dropped 5.6% after missing fourth-quarter profit estimates. Bank of America and Citigroup beat expectations but still saw their shares slip as investors took profits. “It’s not unusual to see a little bit of a pullback,” said Jake Johnston, deputy CIO at Advisors Asset Management. Reuters

The notion of capping credit-card rates is stirring frustrations across the industry. Citigroup CFO Mark Mason warned such a limit “would restrict access to credit” for those who rely on it most. Banks, however, say they remain open to discussions on easing cost-of-living strains. Reuters

Tech stocks took a hit after Reuters reported that Chinese regulators have instructed domestic companies to drop cybersecurity software from about a dozen U.S. and Israeli providers. This move weighed on enterprise security and networking players like Broadcom’s VMware, Palo Alto Networks, and Fortinet.

Economic data came in stronger than anticipated, yet it failed to shift sentiment. U.S. retail sales climbed 0.6% in November, while “core” retail sales — a tighter gauge of underlying demand — rose 0.4%. This suggests consumers stayed active despite delays in data releases caused by a lengthy government shutdown. Reuters

Inflation remains a key factor. The Consumer Price Index climbed 2.7% over the 12 months ending in December, with the core CPI — excluding food and energy — up 2.6%. This keeps the question open on just how fast inflation is truly cooling.

Wholesale inflation remained contained, though not exactly soft. The Producer Price Index, measuring prices firms receive before goods and services hit consumers, climbed 0.2% in November and was 3.0% higher than a year ago. A notable spike in energy costs accounted for much of the increase.

Outside the stock market, demand for hedges remained strong. Gold climbed to new highs, while silver surged past $90 an ounce, fueled by bets on rate cuts and growing geopolitical tensions. “All roads are leading to gold and silver,” said Alex Ebkarian, COO at Allegiance Gold. Reuters

The risk hasn’t vanished: core CPI eased slightly, but underlying pressure—especially from food—remained stubborn. Economists caution the Fed’s favored inflation measure might show more heat once delayed data comes in. New York Fed President John Williams also signaled inflation could hover near 3% into early 2026.

Traders will turn to the Fed’s Beige Book at 2 p.m. ET next—a survey capturing regional business activity and pricing trends—just days before the Jan. 27-28 policy meeting.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next
Previous Story

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Uber stock slips after NYC tipping report targets Uber Eats, as earnings date and new profit metrics loom
Next Story

Uber stock slips after NYC tipping report targets Uber Eats, as earnings date and new profit metrics loom

Go toTop